Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group-Reference-Cited by-同舟云学术

Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group

Published:2020-02 Issue:2 Volume:52 Page:138-142
ISSN:1590-8658
Container-title:Digestive and Liver Disease
language:en
Short-container-title:Digestive and Liver Disease

Author:

D’Amico Ferdinando,Pouillon Lieven,Argollo Marjorie,Hart Ailsa,Fiorino Gionata,Vegni Elena,Radice Simona,Gilardi Daniela,Fazio Maria,Leone Salvo,Bonovas Stefanos^ORCID,Magro Fernando^ORCID,Danese Silvio,Peyrin-Biroulet Laurent

Funder

Pfizer Ltd

Amgen

Samsung Bioepsis Co. Ltd

MICILOR

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference33 articles.

1. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study;van der Valk;Gut,2014

2. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes;Cohen;Drugs,2018

3. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study;Park;Ann Rheum Dis,2013

4. A randomised, double-blind, parallel-group study to demon-strate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when co-administered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study;Yoo;Ann Rheum Dis,2013

5. The nocebo effect: a clinical challenge in the era of biosimilars;Pouillon;Expert Rev Clin Immunol,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Does an Integrated Pharmacist Add Value in the Management of Inflammatory Bowel Disease in the Era of Values-Based Healthcare?;Inflammatory Bowel Diseases;2024-08-29

2. Stakeholder perspectives on the sustainability of the United States biosimilars market;Journal of Managed Care & Specialty Pharmacy;2024-07-16

3. Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey;Journal of Clinical Medicine;2024-05-24

4. Clinical efficacy and nocebo effect following non-medical biosimilar switch in patients with inflammatory bowel disease: A prospective observational study;Digestive and Liver Disease;2024-01

5. Patients’ Perceptions of Biosimilars: A Systematic Review;BioDrugs;2023-09-07